E
Elypta
Molecular diagnostic company focused on preventing cancer mortality by developing a metabolism-based liquid biopsy platform for early detection and monitoring of the disease
About Elypta
Elypta is a Swedish molecular diagnostics company founded in 2017 by Jens Nielsen and Francesco Gatto. The company is focused on reducing cancer mortality through early detection and has developed a metabolism-based liquid biopsy platform.
Read full description
The founders, Jens Nielsen and Francesco Gatto, have a background in systems biology and bioinformatics. Their research on cancer metabolism led to the discovery of a new panel of biomarkers, the glycosaminoglycans (GAGs), which can be used for early cancer detection. This scientific breakthrough is the foundation of Elypta's technology.
Elypta's liquid biopsy platform is designed to detect cancer at an early stage by analyzing the GAGome, the complete set of GAGs in a biological sample. The platform uses a simple blood or urine test to measure the levels of GAGs, which are altered in the presence of a tumor. This allows for the non-invasive detection of multiple types of cancer, even before the appearance of symptoms.
The company's business model is based on the commercialization of its liquid biopsy tests. Elypta is currently conducting clinical studies to validate its technology and plans to launch its first product in the coming years. The company is targeting a wide range of clients, including hospitals, clinical laboratories, and pharmaceutical companies.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Solna kommun, Sweden
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 75.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Health Diagnostics, Spinout, Metabolism, Sustainable Development Goals, Digital Sandbox (EIT Health)
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Elypta.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Mar 2023 | $1M | — | The Roddenberry Foundation | ↗ |
| SUPPORT PROGRAM✓Other financing | Nov 2022 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Elypta is 940 monthly website visits, up 224.1% over the last three months. Elypta's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Chalmers Ventures
Navigare Ventures
European Commission
EIT Health
Industrifonden
Sciety
Norrsken VC
Nina Capital
The Roddenberry Foundation
Series A2 investors entered at this stage
Bonnier Capital
Hillclimber
Other known investors3 additional known investors
Chalmers University of Technology
Falling Walls Foundation
KI Science Park
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elypta on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elypta’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.